These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22090274)

  • 1. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
    Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
    J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
    Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
    Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
    Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
    J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
    Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.
    Fulghesu AM; Manca R; Loi S; Fruzzetti F
    Fertil Steril; 2015 Mar; 103(3):808-14. PubMed ID: 25637475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
    Zheng Z; Li M; Lin Y; Ma Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):271-3. PubMed ID: 12133398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
    Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
    Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
    Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
    Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.
    Gourgari E; Lodish M; Keil M; Sinaii N; Turkbey E; Lyssikatos C; Nesterova M; de la Luz Sierra M; Xekouki P; Khurana D; Ten S; Dobs A; Stratakis CA
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3353-60. PubMed ID: 27336356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptin-replacement therapy for lipodystrophy.
    Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
    N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learned form monogenic forms of severe insulin resistance associated with PCOS/HAIRAN?
    Vigouroux C
    Ann Endocrinol (Paris); 2010 May; 71(3):222-4. PubMed ID: 20362964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS.
    Shorakae S; Ranasinha S; Abell S; Lambert G; Lambert E; de Courten B; Teede H
    Clin Endocrinol (Oxf); 2018 Nov; 89(5):628-633. PubMed ID: 29992612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early metabolic derangements in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Maliqueo M; Codner E; Echiburú B; Crisosto N; Pérez V; Pérez-Bravo F; Cassorla F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4637-42. PubMed ID: 17848407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.